ALPA LABORATORIES LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 112 | 92 | 109 | 112 | 106 |
| EBITDA (ex other income) | 11 | 8 | 8 | 5 | 2 |
| margin % | 9.5 | 8.2 | 7.5 | 4.2 | 2.3 |
| Owners' profit | 0 | 0 | 17 | 0 | 14 |
| EPS, as reported (₹) | 6.67 | 5.90 | 8.01 | 9.34 | 6.71 |
| ROE % · ROCE % | 11.6 · 16.0 | 9.4 · 11.8 | 11.0 · 13.6 | 11.4 · 14.7 | 7.6 · 8.5 |
| Debt / equity (x) | 0.05 | 0.02 | 0.03 | 0.00 | 0.01 |
| Cash from operations | 2 | (5) | 4 | 7 | 11 |
| Capex | (2) | (1) | (6) | (11) | (4) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 25 | 26 | 40 | 19 | 26 | 29 | 31 | 24 |
| Profit before tax | 10 | 9 | 2 | 12 | 0 | 2 | 2 | 1 |
| Net profit | 8 | 9 | (2) | 12 | 0 | 2 | 0 | 1 |
| EPS (₹) | 3.66 | 4.23 | (0.95) | 5.59 | 0.05 | 0.90 | 0.24 | 0.49 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Alpa Laboratories FY26 Annual Report and 38th AGM Notice filed | board shareholder meetings | medium | — | — |
| 7 Sept 2026 · Book Closure Sept 23-30, 2026 for 38th AGM of Alpa Laboratories | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Radhika Biyani appointed as independent director | management changes | medium | — | — |
| 13 Aug 2026 · Alpa Labs Q1 FY27: Revenue up 25% YoY, PAT drops sharply | results | high | — | — |
| 13 Aug 2026 · Alpa Labs Q1 FY27: Revenue up 25% YoY; PAT falls on lower investment gains | results | high | — | — |
| 11 Aug 2026 · Board Meeting Date Clarification - Typo Correction | board shareholder meetings | low | — | — |
| 4 Aug 2026 · Board meeting on Aug 13 to consider Q1 FY26-27 results and AGM notice | results | low | — | — |
| 29 Jul 2026 · Approval in principle for overseas JV in Nigeria with Blueseal Pharmaceuticals | strategic transactions | medium | — | — |
| 27 Jul 2026 · Revised filing after NSE clarification query on Q4 FY26 results | results | medium | — | — |
| 22 Jul 2026 · Independent Director Ms. Jyoti Jain ceases upon tenure completion | management changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 36.3 | 28.9 | 100 of 169 | 41% |
| P/B | 0.7 | 3.3 | 9 of 163 | 95% |
| ROCE | 8.3 | 10.8 | 112 of 183 | 39% |
| ROE | 7.6 | 10.4 | 109 of 171 | 37% |
| Debt / Equity | 0.0 | 0.1 | 53 of 171 | 69% |
| EBITDA margin | 7.6 | 17.5 | 131 of 165 | 21% |
| Revenue growth | 25.2 | 16.3 | 59 of 161 | 64% |
| Profit growth | (91.7) | 30.9 | 144 of 158 | 9% |
| Market cap | 128 | 839 | 128 of 182 | 30% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
